الصفحة 1 من عند 41 النتائج
FEDERALLY SPONSORED RESEARCH STATEMENT
Not applicable.
REFERENCE TO A SEQUENCE LISTING
A "Sequence Listing" with sequences labeled SEQ ID NO: 1-75 is attached hereto. A compact disc containing a Computer Readable Form (CRF) labeled "SEQUENCE LISTING.txt" is incorporated by reference. The copy in CRF
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
The present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to bioisosteres of quinoline and quinazoline derivatives which exhibit protein
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
The present invention relates to the treatment of severe persistent asthma, and in particular severe persistent corticosteroid-dependent or corticosteroid-resistant asthma, comprising administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically
CROSS REFERENCES TO RELATED APPLICATIONS
This application claims priority to European Patent Application No. 17153785.5 filed on Jan. 30, 2017, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds
FIELD OF THE INVENTION
The present invention relates to the field of interfering RNA compositions for silencing spleen tyrosine kinase (Syk) and for treatment of a Syk-related inflammatory condition. Such conditions include allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma,
FIELD OF THE INVENTION
The present invention relates to the field of interfering RNA compositions for silencing spleen tyrosine kinase (Syk) and for treatment of a Syk-related inflammatory condition. Such conditions include allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma,
FIELD OF THE INVENTION
The present invention relates to the field of interfering RNA compositions for silencing spleen tyrosine kinase (Syk) and for treatment of a Syk-related inflammatory condition. Such conditions include allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma,
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
This invention relates to model systems for autoimmune disease. In particular, the invention relates to animals, preferably mice, with a specifically-targeted disruption of a gene encoding a protein tyrosine kinase enzyme of the src family. Mice according to the invention show a variety of